Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
NCT04675294
Recruiting
A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Hoag Hospital, Irvine, California +49 locations
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
NCT05322135
Recruiting
We propose a focused, prospective pilot clinical imaging trial to evaluate 11C-Gln PET/CT followed by 18F-FSPG PET/CT in 20 HNSCC patients. Imaging metrics that are common to PET (e.g. SUVmax, peak or mean) will be determined. This study will also allow the acquisition of additional safety and biodistribution data, as, to date, only a limited number of patients have been evaluated with 11C-Gln as a direct PET imaging biomarker of Gln uptake. To date, no adverse side effects have been observed.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Register for Updates
Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy
NCT05793151
Recruiting
The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual at decreasing delays starting guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are: Does ENDURE decrease delays starting PORT relative to treatment as usual? Does ENDURE decrease racial disparities in delays starting PORT relative to treatment as usual What are the me... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Washington University in St. Louis, Saint Louis, Missouri +3 locations
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer
Register for Updates
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
NCT05712356
Recruiting
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with advanced head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and cholangiocarcinoma. The main questions it aims to answer are: is the new drug plus standard treatment safe and tolerable is the new drug plus standard treatment more effective than standard treatment
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +17 locations
Conditions: Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Cholangiocarcinoma, Esophageal Squamous Cell Carcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Cancer of the Head and Neck, HNSCC, Oropharynx Cancer, Oral Cavity Cancer, Hypopharynx Cancer, Larynx Cancer, Esophagus SCC, Esophagus Cancer, Oral Cavity Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx, Gall Bladder Cancer, Gall Bladder Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
Register for Updates
Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer
NCT00230308
Recruiting
Through this study, we hope to learn more about the mechanisms, which may contribute to development and progression of head and neck cancer. The long-term goal of this study will be to develop new strategies and drugs for the diagnosis and treatment of head and neck cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Head and Neck Cancer
Register for Updates
Study of ALE.C04 in Patients With Head and Neck Cancer
NCT06054477
Recruiting
The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and as monotherapy and to assess anti-tumor activity of ALE.C04 monotherapy and in combination with pembrolizumab in patients with Head and Neck Cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: University of Southern California USC Norris Comprehensive Cancer Center, Los Angeles, California +4 locations
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT04825834
Recruiting
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
Gender:
All
Ages:
50 years and above
Trial Updated:
11/21/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +1 locations
Conditions: Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Kidney Cancer, Stomach Cancer, Colorectal Cancer, Pancreas Cancer, Liver Cancer, Skin Cancer
Register for Updates
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
NCT05076760
Recruiting
This phase I trial is designed in two parts. First as an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) who have a tumor lesion which is accessible for injection will undergo intratumoral injection of MEM-288. Following completion of the monotherapy study portion of the study, an expansion arm is desig... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/20/2023
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Register for Updates
A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer
NCT06145412
Recruiting
The purpose of this study is to test whether treatment with Xevinapant added to standard chemoradiation after surgery is an effective treatment for people with high-risk head and neck cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Head and Neck Cancer
Register for Updates
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871
Recruiting
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study Must agree to follow the reproductive criteria Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures Can give signed informed consent documents Participants in this study will continue to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: UCSF Medical Center at Mission Bay, San Francisco, California +7 locations
Conditions: Breast Cancer, Head and Neck Cancer
Register for Updates
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
NCT04474470
Recruiting
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX® (cetuximab) in adults with recurrent and/or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: California Cancer Associates for Research and Excellence, Encinitas, California +9 locations
Conditions: Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
Register for Updates
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
NCT00900419
Recruiting
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.
Gender:
All
Ages:
Between 21 years and 90 years
Trial Updated:
11/14/2023
Locations: University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado
Conditions: Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition
Register for Updates